Innovent Biologics, Inc., a world-class biopharmaceutical company, and Ascentage Pharma, a global biopharmaceutical company, announce that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted and granted Priority Review designation (in a CDE
